RT期刊文章SR电子T1评估脑源性神经营养因子(BDNF)的影响Val66Met多态性在mRNA转录水平,阿尔茨海默病(AD)风险和认知能力(P2.163)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P2.163 VO 84 14补充A1杰里米·伯吉斯A1密涅瓦Carrasquillo A1 Fanggeng邹A1高Seng柴A1柯蒂斯Younkin A1 Mariet艾伦A1丹尼尔联赛A1茱莉亚首页骗子A1弗农Pankratz说道A1亚莎Nair A1苏米特Middha A1 Sooraj Maharjan A1 Thuy阮A1金伯利Malphrus A1莎拉·林肯A1吉娜Bisceglio A1燕Asmann A1奥托佩德拉泽A1玫瑰花蕾罗伯茨A1约翰卢卡斯A1格伦·史密斯A1罗伯特Ivnik A1玛丽Machulda A1尼尔Graff-Radford A1罗纳德·彼得森A1丹尼斯·迪克森A1史蒂文Younkin A1 Nilufer tan年2015 UL //www.ez-admanager.com/content/84/14_Supplement/P2.163.abstract AB目的:分析BDNF Val66Met变体在转录水平的影响,广告风险和认知功能。背景:发表的荟萃分析显示Val66Met协会增加广告风险和认知能力下降。设计/方法:Val66Met变体是使用一组Taqman试验进行验证。物流或线性回归分析与实施反是Val66Met叮铃声测试相关的基因型与广告地位在高加索病例对照系列(2951年广告,4564年控制),从我们的大脑eGWAS发表和基因表达水平(约公元200年~ 200年non-AD),以及基线认知能力的逻辑内存延迟回忆分数(MRLMD)从梅奥诊所研究衰老的参与者,分别。结果:我们观察到一个提示小脑脑源性神经营养因子mRNA水平下降的趋势相结合的一组广告,non-ADs non-ADs孤独。颞叶皮层没有一致的趋势。我们还观察到一个暗示广告风险下降的趋势(或= 0.92,p = 0.098)的运营商。这种趋势逆转,APOE-ε4该匹配以前公布的数据(或= 1.54,p = 0.13;372例和62控制)。诊断挑逗性的广告出现在低年龄Val66Met运营商(β= -0.39,p = 0.21),发现达到名义意义APOE-ε4比如(β= -2.16,p = 0.01)。 We were unable to detect an association between Val66Met status and MRLMD, regardless of APOE genotype. CONCLUSIONS: Our results suggest that within the cerebellum, decreased BDNF mRNA transcript may be mediated through the Val66Met mutation. Effects of the polymorphism on AD risk appear to be dependent on APOE-ε4 genotype, but age of AD onset appears to be earlier in carriers of the minor allele. We did not detect an association between Val66Met status and cognitive performance as measured by MRLMD.Disclosure: Dr. Burgess has nothing to disclose. Dr. Carrasquillo has nothing to disclose. Dr. Zou has nothing to disclose. Dr. Chai has nothing to disclose. Dr. Younkin has nothing to disclose. Dr. Allen has nothing to disclose. Dr. Serie has nothing to disclose. Dr. Crook has nothing to disclose. Dr. Pankratz has nothing to disclose. Dr. Nair has nothing to disclose. Dr. Middha has nothing to disclose. Dr. Maharjan has nothing to disclose. Dr. Nguyen has nothing to disclose. Dr. Malphrus has nothing to disclose. Dr. Lincoln has nothing to disclose. Dr. Bisceglio has nothing to disclose. Dr. Asmann has nothing to disclose. Dr. Pedraza has nothing to disclose. Dr. Roberts has nothing to disclose. Dr. Lucas has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Ivnik has nothing to disclose. Dr. Machulda has nothing to disclose. Dr. Graff-Radford has received personal compensation for activities with Codman and Cytox as a scientific advisory board member or a consultant. Dr. Graff-Radford has received royalty payments for UpToDate. Dr. Petersen has received personal compensation for activities with Pfizer Inc. and Janssen Alzheimer's Immunotherapy. Dr. Dickson has nothing to disclose. Dr. Younkin has nothing to disclose. Dr. Taner has nothing to disclose.Tuesday, April 21 2015, 7:30 am-12:00 pm